# A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

> **NCT04850118** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beacon Therapeutics** · enrollment: 85 (actual)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** rAAV2tYF-GRK1-hRPGRco
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT04850118
- **Lead sponsor:** Beacon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-14
- **Primary completion:** 2026-06-30
- **Final completion:** 2031-10-31
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850118, "A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04850118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*